Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of VX-661 and ivacaftor in people with cystic fibrosis. , protocol number Vertex VX-661-106

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor in people with CF.

    • Age:

      12 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      11

    • Length of Participation:

      32 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of Vertex and ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-107

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor and will use a placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      25 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation predicted to have residual function. , protocol number Vertex NCT02392234 VX14-661-108

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor and will use a placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      12

    • Length of Participation:

      33 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    Phase 3 study of Vertex 661 and inacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation with a gating defect responsive to inacaftor. , protocol number Vertex VX-661-109

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with inacaftor and will use a placebo control.

    • Age:

      12 Years and Older

    • Mutation(s):

      One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      13

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    Phase 2 study of Vertex 661 and ivacaftor in adults with cystic fibrosis. , protocol number Vertex VX-661-111

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug VX-661 in combination with ivacaftor.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      6

    • Length of Participation:

      60 days

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    An Ocular Safety Study of Kalydeco-Treated Children 11 Years of Age or Younger with CF , protocol number Vertex VX-770-115

    This trial is designed to evaluate the risk of of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of children with Cystic Fibrosis who are 11 years of age or younger at the time of ivacaftor (Kalydeco) treatment initiation and are receiving or planning to receive commercially-available ivacaftor (Kalydeco) in the US.

    • Age:

      6 Years to 11 Years

    • Mutation(s):

      One Copy F508del or No Copies F50del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      2 years

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of lumacaftor and ivacaftor in which cystic fibrosis with advanced lung disease. , protocol number Vertex VX-809-106

    This study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drugs lumacaftor and ivacaftor in people with advanced lung disease.

    • Age:

      12 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      Less than 40%

    • Number of Visits:

      14

    • Length of Participation:

      52 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionClosed to enrollment Location: USA

    Phase 3 study of lumarcaftor and ivacaftor in children with cystic fibrosis , protocol number Vertex VX-809-109

    This study is taking place at multiple care centers across the U.S. It will evaulate the safety and effectiveness of the drugs lumacaftor and ivacaftor in children with cystic fibrosis.

    • Age:

      6 Years to 11 Years

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      70% to 105%

    • Number of Visits:

      5

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US sites

    Phase 2 study of CTP-656 in aduts with CF who are currently taking ivacaftor (Kalydeco) , protocol number CP656.2001 ClinicalTrials.gov Identifier: NCT02971839

    This study will evaluate the safety and effectiveness of the drug, CTP-656 in adults with Cystic Fibrosis who have a gating mutation and are currently taking ivacaftor (KALYDECO)

    • Age:

      18 years and older

    • Mutation(s):

      One copy F508del or no copies F508del

    • FEV1% Predicted:

      60-90%

    • Number of Visits:

      6

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • BehavioralEnrolling Location: USA

    Phase 4 study of adherence to lumacaftor/ivacaftor in people with CF , protocol number Vertex VX-809-114

    This study is taking place at multiple care centres across the US. It will look at the impact of using a smart device that monitors medication use on adherence to lumacaftor/ivacaftor.

    • Age:

      16 Years and Older

    • Mutation(s):

      Two Copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      7

    • Length of Participation:

      48 weeks

    Contact us about this clinical Trial >
  • Displaying results 121-130 (of 130)
     |<  <  4 - 5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 >  >|